RVNC - Revance wins FDA label expansion for lead product
2023-08-14 08:25:28 ET
More on Revance Therapeutics
- Revance Therapeutics, Inc. ( RVNC ) Q2 2023 Earnings Call Transcript
- Revance Therapeutics: PDUFA Catalyst 2023 And Increased Revenues
- Revance surges 45% as it sees revenue from RHA collection to be between $34M and $35M
- Revance Therapeutics stock slides on pricing $200.0M upsized stock offering
- Revance nears eleven-month high as Botox rival gets FDA approval
- Revance climbs 14% as FDA approves facial injectable for frown lines
For further details see:
Revance wins FDA label expansion for lead product